Faricimab

法瑞西单抗

Report date: 2026/04/24 20:01:59
First In Class

Base Information

Drug NameFaricimab
Drug Alias NameFaricimab-svoaVabysmo罗视佳RG-7716RO-6867461
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAngiopoietin-2 inhibitorsVascular endothelial growth factor A inhibitors
TargetsAngiopoietin-2Vascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaPolypoidal choroidal vasculopathyDiabetes Complications +[14] 
Global Approved IndicationsDiabetic macular oedemaDiabetes ComplicationsWet age-related macular degeneration +[5] 
Approved Indications in ChinaDiabetic macular oedemaMacular Degeneration
Original Approved Country/TerritoryUnited States
Original Approved Date2022/01/28
Country/TerritoryCzechiaBulgariaCanada +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche LtdGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesBaghdad college of medicineYeungnam UniversityJaeb Center For Health Research Inc +[10] 
Inactive CompaniesRoche Pharma (Schweiz) Ag
Active IndicationsDiabetic macular oedemaPolypoidal choroidal vasculopathyDiabetes Complications +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeS01LA09
Related LinksDrugBankKEGG